Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
Coherus BioSciences (CHRS) reported Q2 2021 net product revenue of $88 million from UDENYCA®, with a net loss of $29.9 million. The company is advancing its portfolio, including a BLA for toripalimab expected to be submitted soon, alongside submissions for biosimilars CHS-201 and CHS-1420. R&D expenses surged to $54.8 million due to intensified development efforts. Despite a cash balance of $454.4 million, the company anticipates $370M-$400M in total R&D and SG&A expenses for the full year, reflecting high investment in product development and commercialization.
- Projected launch of four approved products in the U.S. in one year, expanding revenue potential.
- Successful completion of a $50 million share acquisition from Junshi Biosciences.
- Net loss of $29.9 million, significantly down from a net income of $59 million in Q2 2020.
- R&D expenses escalated to $54.8 million, up from $26.2 million in Q2 2020, indicating higher costs.
- UDENYCA® net sales decreased from $135.7 million in Q2 2020 to $88 million in Q2 2021.
–1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021
in the toripalimab BLA —
– CHS-201 (Lucentis® biosimilar) BLA submitted to FDA –
–CHS-1420 (Humira® biosimilar) BLA review progressing with December target action date –
– Second quarter 2021 UDENYCA® net sales of
– Conference call today at 5:00 p.m. ET –
REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2021. The Company also provided a progress update on its PD-1 blocking antibody, toripalimab, its lead immuno-oncology candidate for the potential treatment of various solid tumors, as well as other late-stage pipeline product candidates including CHS-201, a biosimilar Lucentis® (ranibizumab), CHS-1420, a wholly owned biosimilar Humira® (adalimumab), and CHS-305, a biosimilar Avastin® (bevacizumab).
“With two biosimilar BLAs currently under FDA review and a toripalimab BLA submission expected to be completed soon, we are making strong progress toward our objective to diversify and grow our product portfolio,” said Denny Lanfear, Coherus CEO. “We project that within one year we will have four approved products, including UDENYCA®, in the United States, and that in 2023 we will have five marketed products generating revenue to invest in our immuno-oncology business.”
SECOND QUARTER 2021 FINANCIAL HIGHLIGHTS
- Net product revenue, consisting of net sales of UDENYCA® (pegfilgrastim-cbqv) was
$88 million . - GAAP net loss of
$29.9 million was primarily driven by increased R&D and regulatory expenses to support the advancement of toripalimab and the biosimilar pipeline product candidates. - Non-GAAP net loss was
$27.3 million . - At June 30, 2021, Coherus had cash, cash equivalents and marketable securities of
$454.4 million . - In April 2021, the Company received
$50 million from Junshi Biosciences’ acquisition of 2,491,988 shares of Coherus stock.
PIPELINE HIGHLIGHTS
Coherus is planning an analyst day event in the fourth quarter of 2021
Toripalimab, a PD-1 blocking antibody product candidate, in collaboration with Junshi Biosciences:
- Following a recent meeting with the United States Food and Drug Administration (“FDA”), Coherus’ immuno-oncology partner, Junshi Biosciences, plans to submit the biologics license application (“BLA”) for toripalimab in combination with chemotherapy for 1st line treatment of metastatic or recurrent nasopharyngeal carcinoma (“NPC”) concurrently with toripalimab monotherapy in second or third line treatment of recurrent or metastatic NPC. Junshi Biosciences expects to complete the BLA submission for these indications later this quarter.
- Data from a Phase 3 clinical trial evaluating toripalimab for the treatment of non-small cell lung cancer will be presented in September at the World Conference on Lung Cancer.
- Data from a Phase 3 clinical trial evaluating toripalimab for the treatment of esophageal squamous cell carcinoma will be presented in September at the annual meeting of the European Society for Medical Oncology.
CHS-201, a biosimilar Lucentis® (ranibizumab) product candidate in collaboration with Bioeq AG:
- Bioeq AG recently submitted the CHS-201 BLA. Pending acceptance of the BLA by the FDA, Coherus anticipates a mid-2022 target action date for the BLA review.
CHS-1420, a wholly owned biosimilar Humira® (adalimumab) product candidate:
- The review of the CHS-1420 BLA is progressing with a target action date of December 2021. Coherus plans to launch CHS-1420 on or after July 1, 2023, if approved.
CHS-305, a biosimilar Avastin® (bevacizumab) product candidate in collaboration with Innovent Biologics (Suzhou) Co. Ltd:
- Coherus is conducting the three-way pharmacokinetic study to facilitate the potential CHS-305 BLA submission.
SECOND QUARTER 2021 FINANCIAL RESULTS
Net product revenue, consisting of net sales of UDENYCA®, was
Cost of goods sold (COGS), increased to
Research and development (R&D) expense for the three months ended June 30, 2021 was
Selling, general and administrative (SG&A) expense for the three months ended June 30, 2021 was
Net loss for the second quarter of 2021 was
Non-GAAP net loss for the second quarter of 2021 was
Cash, cash equivalents and investments in marketable securities were
2021 FINANCIAL OUTLOOK
Excluding the upfront payment made to Junshi Biosciences in the first quarter, Coherus projects full year 2021 R&D and SG&A expenses in a range of
This financial guidance excludes the effects of any potential future strategic acquisitions, collaborations or investments, the exercise of rights or options related to collaboration programs, and any other transactions or items not yet identified or quantified. This guidance is subject to a number of risks and uncertainties. See Forward-Looking Statements described in the section below and the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 to be filed with the Securities & Exchange Commission on August 5, 2021.
Conference Call Information
When: Thursday, August 5, 2021 starting at 5:00 p.m. ET
Dial-in: (844) 452-6826 (Toll-Free U.S. and Canada) or (765) 507-2587 (International)
Conference ID: 9146617
Webcast: https://investors.coherus.com/upcoming-events
Please dial-in 15 minutes early to ensure a timely connection to the call.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch toripalimab, an anti-PD-1 antibody, as well as biosimilars of Lucentis®, Humira®, and Avastin®, if approved.
For additional information, please visit www.coherus.com.
UDENYCA® is a trademark of Coherus BioSciences, Inc.
Avastin® and Lucentis® are registered trademarks of Genentech, Inc.
Humira® is a registered trademark of AbbVie Inc.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ ability to maintain UDENYCA® market share and position as leading pegfilgrastim biosimilar in the United States; Coherus’ ability to generate increased revenue from its UDENYCA business with anticipated market share growth, assuming treatment patterns begin to normalize as the general population is vaccinated against COVID-19; Coherus’ ability to expand its addressable market opportunity and to lay the foundation for long-term growth across its biosimilar product portfolio and immuno-oncology product pipeline; Coherus’ ability to advance the Company’s oncology biosimilar candidate to Avastin® (bevacizumab) in-licensed from Innovent toward an expected 351(k) BLA submission with the U.S. FDA in 2021, the timing of required interactions with the FDA; the risk that the product may not be approved on time, if at all; Coherus’ ability to launch Innovent’s biosimilar candidate to Avastin® in the United States; Coherus’ ability to facilitate Bioeq’s resubmission of a BLA with the FDA for the ophthalmology biosimilar candidate to Lucentis® (ranibizumab) in mid-2021 and Coherus’ ability to launch the product, if approved; Coherus’ ability to facilitate Junshi Biosciences’ submission of a toripalimab BLA with the FDA for nasopharyngeal carcinoma in 2021 and for additional indications, including lung cancer, over the next three years; the timing of the FDA’s approval decision for CHS-1420, a Humira® (adalimumab) biosimilar, and the risk that the product may not be approved on time, if at all; Coherus’ ability to continue other CHS-1420 activities to advance toward a projected market entry in the United States on or after July 1, 2023; and Coherus’ ability to meet its R&D and SG&A expenses guidance for the full fiscal year 2021. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ biosimilar drug candidates; and the risks and uncertainties of possible patent litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the three and six months ended June 30, 2021, to be filed with the Securities and Exchange Commission on August 5, 2021 and its future periodic reports to be filed with the Securities and Exchange Commission. Our results for the quarter ended June 30, 2021 are not necessarily indicative of our operating results for any future periods.
Coherus BioSciences, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||
| Revenue: | |||||||||||||||||
| Net product revenue | $ | 87,643 | $ | 135,674 | $ | 170,677 | $ | 251,854 | |||||||||
| Operating expenses: | |||||||||||||||||
| Cost of goods sold | 16,696 | 10,139 | 24,207 | 16,994 | |||||||||||||
| Research and development | 54,766 | 26,173 | 258,258 | 59,280 | |||||||||||||
| Selling, general and administrative | 40,345 | 34,052 | 79,736 | 69,402 | |||||||||||||
| Total operating expenses | 111,807 | 70,364 | 362,201 | 145,676 | |||||||||||||
| (Loss) Income from operations | (24,164 | ) | 65,310 | (191,524 | ) | 106,178 | |||||||||||
| Interest expense | (5,747 | ) | (5,408 | ) | (11,395 | ) | (9,839 | ) | |||||||||
| Other income, net | 11 | 423 | 72 | 491 | |||||||||||||
| Net (loss) income before income taxes | (29,900 | ) | 60,325 | (202,847 | ) | 96,830 | |||||||||||
| Income tax provision | — | 1,294 | — | 2,227 | |||||||||||||
| Net (loss) income | $ | (29,900 | ) | $ | 59,031 | $ | (202,847 | ) | $ | 94,603 | |||||||
| Net (loss) income per share: | |||||||||||||||||
| Basic | $ | (0.40 | ) | $ | 0.83 | $ | (2.73 | ) | $ | 1.33 | |||||||
| Diluted | $ | (0.40 | ) | $ | 0.70 | $ | (2.73 | ) | $ | 1.20 | |||||||
| Weighted-average number of shares used in computing net (loss) income per share: | |||||||||||||||||
| Basic | 75,559,697 | 71,099,773 | 74,203,858 | 70,880,979 | |||||||||||||
| Diluted | 75,559,697 | 88,660,280 | 74,203,858 | 83,775,353 | |||||||||||||
Coherus BioSciences, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| June 30, | December 31, | ||||||
| 2021 | 2020 | ||||||
| Assets | |||||||
| Cash and cash equivalents | $ | 329,738 | $ | 541,158 | |||
| Investments in marketable securities | 124,683 | — | |||||
| Trade receivables, net | 141,825 | 157,046 | |||||
| Inventory | 96,081 | 92,189 | |||||
| Other assets | 47,215 | 51,256 | |||||
| Total assets | $ | 739,542 | $ | 841,649 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Accrued rebates, fees and reserves | $ | 83,758 | $ | 81,529 | |||
| Convertible notes due 2022* | 80,605 | 79,885 | |||||
| Convertible notes due 2022 - related parties* | 26,868 | 26,628 | |||||
| Convertible notes due 2026 | 223,655 | 223,029 | |||||
| Term loan - current portion | 11,538 | — | |||||
| Term loan-non - current portion | 63,420 | 74,481 | |||||
| Other liabilities | 93,478 | 75,123 | |||||
| Total stockholders' equity | 156,220 | 280,974 | |||||
| Total liabilities and stockholders’ equity | $ | 739,542 | $ | 841,649 | |||
* The Convertible notes due 2022 and the Convertible notes due 2022 - related parties were classified in current liabilities as of June 30, 2021 and in non-current liabilities as of December 31, 2020.
Coherus BioSciences, Inc.
Condensed Consolidated Cash Flow
(in thousands)
(unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||
| Cash, cash equivalents and restricted cash at beginning of the period | $ | 259,929 | $ | 193,692 | $ | 541,598 | $ | 177,908 | |||||||||
| Net cash (used in) provided by operating activities | $ | (188 | ) | $ | 60,191 | $ | 1,179 | $ | 73,668 | ||||||||
| Purchases of investments in marketable securities | — | (231,864 | ) | (140,330 | ) | (231,864 | ) | ||||||||||
| Proceeds from maturities of investments in marketable securities | 15,000 | — | 15,000 | — | |||||||||||||
| Upfront license fee payments* | 9,000 | (5,000 | ) | (136,000 | ) | (5,000 | ) | ||||||||||
| Cash used in other investing activities | (415 | ) | (2,384 | ) | (560 | ) | (4,000 | ) | |||||||||
| Net cash provided by (used in) investing activities | $ | 23,585 | $ | (239,248 | ) | $ | (261,890 | ) | $ | (240,864 | ) | ||||||
| Proceeds from issuance of Convertible Notes due 2026, net of issuance costs | — | 222,830 | — | 222,830 | |||||||||||||
| Purchase of capped call options related to convertible notes due 2026 | — | (18,170 | ) | — | (18,170 | ) | |||||||||||
| Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs | 40,903 | — | 40,903 | — | |||||||||||||
| Proceeds from issuance of common stock upon exercise of stock options | 4,117 | 3,302 | 8,446 | 8,105 | |||||||||||||
| Proceeds from purchase under the employee stock purchase plan | 1,985 | 2,557 | 1,985 | 2,557 | |||||||||||||
| Cash used in other financing activities | (153 | ) | (97 | ) | (2,043 | ) | (977 | ) | |||||||||
| Net cash provided by financing activities | $ | 46,852 | $ | 210,422 | $ | 49,291 | $ | 214,345 | |||||||||
| Net increase in cash, cash equivalents and restricted cash | $ | 70,249 | $ | 31,365 | $ | (211,420 | ) | $ | 47,149 | ||||||||
| Cash, cash equivalents and restricted cash at end of the period | $ | 330,178 | $ | 225,057 | $ | 330,178 | $ | 225,057 | |||||||||
| Reconciliation of cash, cash equivalents, and restricted cash | |||||||||||||||||
| Cash and cash equivalents | $ | 329,738 | 224,617 | $ | 329,738 | 224,617 | |||||||||||
| Restricted cash balance | 440 | 440 | 440 | 440 | |||||||||||||
| Cash, cash equivalents and restricted cash | $ | 330,178 | $ | 225,057 | $ | 330,178 | $ | 225,057 | |||||||||
* 2021 payments includes license fees of
Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, Coherus has also included in this press release non-GAAP net income, and the related per share measures, which exclude from net (loss) income, and the related per share measures, stock-based compensation expense, upfront and milestone payments under the license agreements, costs related to termination of a research and development program as part of a strategic realignment of research and development resources toward other development programs and the related income tax effect of those non-GAAP adjustments. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.
Coherus believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.
Coherus BioSciences, Inc.
Reconciliation of GAAP Net (Loss) Income to Non-GAAP Net (Loss) Income
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||
| GAAP net (loss) income | $ | (29,900 | ) | $ | 59,031 | $ | (202,847 | ) | $ | 94,603 | |||||||
| Adjustments: | |||||||||||||||||
| Stock-based compensation expense | 11,595 | 9,425 | 28,479 | 18,980 | |||||||||||||
| Upfront license fees* | (9,000 | ) | — | 136,000 | 5,000 | ||||||||||||
| Costs related to termination of CHS-2020 development program | — | — | 11,503 | — | |||||||||||||
| Income tax effect of the above adjustments | — | (202 | ) | — | (552 | ) | |||||||||||
| Non-GAAP net (loss) income | $ | (27,305 | ) | $ | 68,254 | $ | (26,865 | ) | $ | 118,031 | |||||||
| GAAP net (loss) income per share, basic | $ | (0.40 | ) | $ | 0.83 | $ | (2.73 | ) | $ | 1.33 | |||||||
| GAAP net (loss) income per share, diluted | $ | (0.40 | ) | $ | 0.70 | $ | (2.73 | ) | $ | 1.20 | |||||||
| Non-GAAP net (loss) income per share, basic | $ | (0.36 | ) | $ | 0.96 | $ | (0.36 | ) | $ | 1.67 | |||||||
| Non-GAAP net (loss) income per share, diluted | $ | (0.36 | ) | $ | 0.81 | $ | (0.36 | ) | $ | 1.48 | |||||||
| Shares used in computing basic net (loss) income per share | 75,559,697 | 71,099,773 | 74,203,858 | 70,880,979 | |||||||||||||
| Shares used in computing diluted net (loss) income per share | 75,559,697 | 88,660,280 | 74,203,858 | 83,775,353 | |||||||||||||
* 2021 expense includes license fees of
Contact
McDavid Stilwell
Chief Financial Officer
Coherus BioSciences, Inc.
IR@coherus.com
+1 (650) 395-0152
FAQ
What were Coherus BioSciences' Q2 2021 financial results?
What is the status of toripalimab's BLA submission?
What are the financial projections for Coherus in 2021?
How did UDENYCA® sales perform in Q2 2021?
